These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1270 related items for PubMed ID: 12715951

  • 1. High dose chemotherapy followed by autologous haemopoietic stem cell transplant in multiple myeloma.
    Kumar L, Raju GM, Ganessan K, Shawgi S, Menon H, Wadhwa J, Sharma A, Singh R, Kochupillai V.
    Natl Med J India; 2003; 16(1):16-21. PubMed ID: 12715951
    [Abstract] [Full Text] [Related]

  • 2. Randomized comparison of granulocyte colony-stimulating factor versus granulocyte-macrophage colony-stimulating factor plus intensive chemotherapy for peripheral blood stem cell mobilization and autologous transplantation in multiple myeloma.
    Arora M, Burns LJ, Barker JN, Miller JS, Defor TE, Olujohungbe AB, Weisdorf DJ.
    Biol Blood Marrow Transplant; 2004 Jun; 10(6):395-404. PubMed ID: 15148493
    [Abstract] [Full Text] [Related]

  • 3. Early harvest and late transplantation as an effective therapeutic strategy in multiple myeloma.
    Gertz MA, Lacy MQ, Inwards DJ, Chen MG, Pineda AA, Gastineau DA, Greipp PR, Lust JA, Tefferi A, Witzig TE, Kyle RA, Litzow MR.
    Bone Marrow Transplant; 1999 Feb; 23(3):221-6. PubMed ID: 10084252
    [Abstract] [Full Text] [Related]

  • 4. Autologous peripheral blood stem cell transplantation as first line treatment of multiple myeloma: an Italian Multicenter Study.
    Tribalto M, Amadori S, Cudillo L, Caravita T, Del Poeta G, Meloni G, Avvisati G, Petrucci MT, Pulsoni A, Leone G, Sica S, Martelli M, Tabilio A, Fioritoni G, Majolino I, Mandelli F.
    Haematologica; 2000 Jan; 85(1):52-8. PubMed ID: 10629592
    [Abstract] [Full Text] [Related]

  • 5. High-dose chemotherapy, autologous bone marrow or stem cell transplantation and post-transplant consolidation chemotherapy in patients with advanced breast cancer.
    Tallman MS, Rademaker AW, Jahnke L, Brown SG, Bauman A, Mangan C, Kelly C, Rubin H, Kies MS, Shaw J, Kiel K, Gordon LI, Gradishar WJ, Winter JN.
    Bone Marrow Transplant; 1997 Nov; 20(9):721-9. PubMed ID: 9384473
    [Abstract] [Full Text] [Related]

  • 6. A feasibility study of multiple cycle therapy with melphalan, thiotepa, and paclitaxel followed by mitoxantrone, thiotepa, and paclitaxel with autologous hematopoietic cell support for metastatic breast cancer.
    Hu WW, Long GD, Stockerl-Goldstein KE, Johnston LJ, Chao NJ, Negrin RS, Blume KG.
    Clin Cancer Res; 1999 Nov; 5(11):3411-8. PubMed ID: 10589752
    [Abstract] [Full Text] [Related]

  • 7. Complete remission status before autologous stem cell transplantation is an important prognostic factor in patients with multiple myeloma undergoing upfront single autologous transplantation.
    Kim JS, Kim K, Cheong JW, Min YH, Suh C, Kim H, Jo DY, Ryoo HM, Yoon SS, Lee JH, Korean Multiple Myeloma Working Party.
    Biol Blood Marrow Transplant; 2009 Apr; 15(4):463-70. PubMed ID: 19285634
    [Abstract] [Full Text] [Related]

  • 8. Autologous transplantation in multiple myeloma: a GITMO retrospective analysis on 290 patients. Gruppo Italiano Trapianti di Midollo Osseo.
    Majolino I, Vignetti M, Meloni G, Vegna ML, Scimè R, Tringali S, Amaddii G, Coser P, Tribalto M, Raimondi R, Bergonzi C, Sajeva MR, Sica S, Ferrando F, Messina G, Mandelli F.
    Haematologica; 1999 Sep; 84(9):844-52. PubMed ID: 10477460
    [Abstract] [Full Text] [Related]

  • 9. Thiotepa, busulfan, cyclophosphamide (TBC) and autologous hematopoietic transplantation: an intensive regimen for the treatment of multiple myeloma.
    Shimoni A, Smith TL, Aleman A, Weber D, Dimopoulos M, Anderlini P, Andersson B, Claxton D, Ueno NT, Khouri I, Donato M, Korbling M, Alexanian R, Champlin R, Giralt S.
    Bone Marrow Transplant; 2001 Apr; 27(8):821-8. PubMed ID: 11477439
    [Abstract] [Full Text] [Related]

  • 10. Transplantation as salvage therapy for high-risk patients with myeloma in relapse.
    Lee CK, Barlogie B, Zangari M, Fassas A, Anaissie E, Morris C, Van Rhee F, Cottler-Fox M, Thertulien R, Muwalla F, Mazher S, Badros A, Tricot G.
    Bone Marrow Transplant; 2002 Dec; 30(12):873-8. PubMed ID: 12476279
    [Abstract] [Full Text] [Related]

  • 11. High-dose chemotherapy with autologous stem cell transplantation for multiple myeloma: what predicts the outcome? Experience from a developing country.
    Kumar L, Ghosh J, Ganessan P, Gupta A, Hariprasad R, Kochupillai V.
    Bone Marrow Transplant; 2009 Mar; 43(6):481-9. PubMed ID: 18978818
    [Abstract] [Full Text] [Related]

  • 12. Fludarabine/melphalan conditioning for allogeneic transplantation in patients with multiple myeloma.
    Giralt S, Aleman A, Anagnostopoulos A, Weber D, Khouri I, Anderlini P, Molldrem J, Ueno NT, Donato M, Korbling M, Gajewski J, Alexanian R, Champlin R.
    Bone Marrow Transplant; 2002 Sep; 30(6):367-73. PubMed ID: 12235521
    [Abstract] [Full Text] [Related]

  • 13. Autologous stem cell transplantation in multiple myeloma: improved survival in nonsecretory multiple myeloma but lack of influence of age, status at transplant, previous treatment and conditioning regimen. A single-centre experience in 127 patients.
    Terpos E, Apperley JF, Samson D, Giles C, Crawley C, Kanfer E, Olavarria E, Goldman JM, Rahemtulla A.
    Bone Marrow Transplant; 2003 Feb; 31(3):163-70. PubMed ID: 12621476
    [Abstract] [Full Text] [Related]

  • 14. Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: final results of phase III US Intergroup Trial S9321.
    Barlogie B, Kyle RA, Anderson KC, Greipp PR, Lazarus HM, Hurd DD, McCoy J, Moore DF, Dakhil SR, Lanier KS, Chapman RA, Cromer JN, Salmon SE, Durie B, Crowley JC.
    J Clin Oncol; 2006 Feb 20; 24(6):929-36. PubMed ID: 16432076
    [Abstract] [Full Text] [Related]

  • 15. High-dose therapy and autologous peripheral blood stem cells transplantation followed by a very low reduced intensity regimen with fludarabine + cyclophosphamide and allograft improve complete remission rate in de novo multiple myeloma patients.
    Martino M, Console G, Irrera G, Praticò G, Stelitano C, Callea V, Morabito F, Quartarone E, Musolino C, Piro E, Brugiatelli M, Iacopino P.
    Am J Hematol; 2006 Dec 20; 81(12):973-8. PubMed ID: 16888786
    [Abstract] [Full Text] [Related]

  • 16. High-dose thiotepa, melphalan and carboplatin (TMCb) followed by autologous stem cell transplantation in patients with advanced breast cancer: a retrospective evaluation.
    Demirer T, Uysal VA, Ayli M, Genc Y, Ilhan O, Koc H, Dagli M, Arat M, Gunel N, Fen T, Dincer S, Ustael N, Yildiz M, Ustun T, Seyrek E, Ozet G, Muftuoglu O, Akan H.
    Bone Marrow Transplant; 2003 May 20; 31(9):755-61. PubMed ID: 12732881
    [Abstract] [Full Text] [Related]

  • 17. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma.
    Child JA, Morgan GJ, Davies FE, Owen RG, Bell SE, Hawkins K, Brown J, Drayson MT, Selby PJ, Medical Research Council Adult Leukaemia Working Party.
    N Engl J Med; 2003 May 08; 348(19):1875-83. PubMed ID: 12736280
    [Abstract] [Full Text] [Related]

  • 18. "Short course" bortezomib plus melphalan and prednisone as induction prior to transplant or as frontline therapy for nontransplant candidates in patients with previously untreated multiple myeloma.
    Gasparetto C, Gockerman JP, Diehl LF, de Castro CM, Moore JO, Long GD, Horwitz ME, Keogh G, Chute JP, Sullivan KM, Neuwirth R, Davis PH, Sutton LM, Anderson RD, Chao NJ, Rizzieri D.
    Biol Blood Marrow Transplant; 2010 Jan 08; 16(1):70-7. PubMed ID: 19733251
    [Abstract] [Full Text] [Related]

  • 19. Salvage chemotherapy with mini-BEAM for relapsed or refractory Hodgkin's disease prior to autologous peripheral blood stem cell transplantation.
    Fernández-Jiménez MC, Canales MA, Ojeda E, de Bustos JG, Aguado MJ, Hernández-Navarro F.
    Haematologica; 1999 Nov 08; 84(11):1007-11. PubMed ID: 10553161
    [Abstract] [Full Text] [Related]

  • 20. [High-dose chemotherapy and autologous stem cell transplantation for refractory and relapsing Hodgkin's disease as first-line therapy-- studies at Sheba Medical Center--Tel Hashomer].
    Avigdor A, Hardan I, Shpilberg O, Raanani P, Grotto I, Ben-Bassat I.
    Harefuah; 2000 Sep 08; 139(5-6):174-9, 248, 247. PubMed ID: 11062945
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 64.